HOMEPAGE
Fully Diluted Subscribe

Nasdaq · Biotech stocks database

IOVA — Iovance Biotherapeutics Inc.

IOVA (Iovance Biotherapeutics Inc.) stock: $8.04, $3.64B market cap, $376.3M cash, $3.27B EV, $3.90B fully diluted market cap. Next expected readout: Nov-26. Lead program: Lifileucel plus Pembrolizumab (Metastatic Melanoma), Phase 3. Data from Fully Diluted's biotech stocks database.

What they do

We are a commercial-stage biopharmaceutical company pioneering a transformational approach to treating cancer. Our mission is to be the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte, or TIL, cell therapies for patients with solid tumor cancers.

Source: 10-K FY2025 via SEC EDGAR

Share price
$8.04
Market cap
$3,641.9M
Cash
$376.3M
Enterprise value
$3,265.6M

Balance sheet

Cash$376.3M
Debt$0.0M
Net cash$376.3M
Enterprise value$3,265.6M
Basic shares462.7M shares
Fully diluted shares485.6M shares
Fully diluted market cap$3,904.6M
Cash per share$0.81
Quarterly burn$60.8M
Cash runway4.9 quarters

Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.

Share structure

Common
453.0M
Pre-funded warrants
0.0M
Options
17.6M
RSUs
12.7M
Warrants
0.0M
Converts
0.0M
Conv preferred
2.0M
ESPP reserve
0.4M
FDSO
485.6M

Cap table as of 2026-06-30.

Price history

Loading IOVA daily closes…

Loading price history…

Next catalyst

lifileucel (IOV-LUN-202) · Est. Nov 15, 2026 · quarter midpoint · guided Now

Recently reported

Lifileucel plus Pembrolizumab Phase 2 Mixed · 2026-10-29
IOV-LUN-202
Primary: Objective response rate (ORR) in Cohorts 1 and 2 of the Phase 2 IOV-LUN-202 trial of lifileucel in previously treated non-squamous mNSCLC (data cutoff October 14, 2026) — 24.6% (17 of 69 patients; 15 confirmed responses and 2 unconfirmed partial responses), consistent with the 25.6% ORR previously reported in 39 patients
· KRAS wild-type subgroup ORR 43.3% (13 of 30) versus 11.4% (4 of 35) in KRAS-mutant disease; both complete responses occurred in KRAS wild-type tumors
· Biomarker-enriched subgroup (KRAS wild-type, HER2 wild-type, current or former smoker) ORR 59.1% (13 of 22); KRAS wild-type + HER2 wild-type subgroup ORR 52.0% (13 of 25)
· Frontline Cohort 3A of IOV-COM-202 (lifileucel plus pembrolizumab): 6 of 7 biomarker-matched patients responded, ORR 85.7%
· Cohorts 1 and 2 completing enrollment, approximately 80 patients expected in the final dataset; sBLA for lifileucel in non-squamous mNSCLC planned for 2027
· POSITILITY biomarker-enriched cohort with registrational intent begins enrollment in November 2026
Safety: Response durability and safety remained consistent with previous reports; the updated reduced-dose lymphodepletion regimen improved the overall safety profile; no specific adverse-event rates disclosed in the release
Source release →
Lifileucel Phase 2 Mixed · 2026-10-26
Primary: Objective response rate (ORR) per RECIST v1.1 in a pilot trial of one-time lifileucel monotherapy in metastatic undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated liposarcoma (DDLPS) — Among the first eight evaluable patients, physician-assessed confirmed ORR by RECIST v1.1 was 50%. Four partial responses (2 in UPS and 2 in DDLPS) were all ongoing (at 6+, 26+, 40+, and 46+ weeks) as of the data cut-off on September 9, 2026
· The eight evaluable patients were refractory to prior lines of systemic therapy (range: 1-7)
· SARATOGA (NCT07741877) is a registrational Phase 2 clinical trial of lifileucel in advanced (metastatic or unresectable) UPS or DDLPS refractory to at least one prior line of anthracycline-based chemotherapy, now enrolling
· The U.S. Food and Drug Administration (FDA) granted fast track designation for lifileucel in advanced UPS and DDLPS in the second quarter of 2026 based on initial results from the pilot trial
Safety: The safety profile was consistent with the lifileucel treatment regimen across other indications (no specific adverse-event numbers disclosed in the release)
Source release →
Lifileucel plus Pembrolizumab Phase 2 Positive · 2026-10-23
IOV-COM-202
Primary: Final Phase 2 analysis of Cohort 1A of IOV-COM-202 (NCT03645928): physician-assessed confirmed objective response rate (ORR) by RECIST v1.1 for one-time lifileucel plus pembrolizumab in frontline advanced melanoma (24 patients) — Confirmed ORR was 62.5% (15/24; 95% CI: 40.6, 81.2), including a 29.2% complete response rate; disease control rate 83.3% (20/24)
· Median overall survival was not reached at a median study follow-up of 50.9 months
· Median duration of response was not reached (range: 4.3 to 57.7+ months) at a median follow-up of 26.9 months for DOR
· Median progression-free survival was 19.8 months (95% CI: 3.6 months to not reached)
· Median PFS after second line of therapy was 34.3 months
· T-cell receptor sequencing detected clones from the infused lifileucel product in peripheral blood for as long as 12 months after infusion (n=13)
· Data support the ongoing Phase 3 TILVANCE-301 trial (NCT05727904) in frontline advanced melanoma
Safety: Safety was consistent with the underlying disease and the known safety profiles of one-time lifileucel and pembrolizumab; late adverse events were consistent with continuous use of pembrolizumab monotherapy
Source release →
Get the weekly biotech catalyst rundown.
Cash runways, financings, and trial readouts for all 721 stocks.
Subscribe to Compounding Ego